City Therapeutics (CTY) Director Nelsen Buys $3.1M of Stock
Key Points
- City Therapeutics, Inc. director Robert Nelsen bought 170,000 shares on October 19, 2026, paying $18.00 per share for a total investment of $3.06 million.
- The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission, growing the director's total holding by about 1.26% to 13,692,507 shares.
- City Therapeutics operates as a Cambridge, Massachusetts-based biotechnology firm focused on RNA interference treatments, holding a market capitalization of roughly $1.08 billion.
Get City Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $CTY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated City Therapeutics, Inc. alert may contain errors. Disclosures
Director Robert Nelsen picked up 170,000 shares of City Therapeutics, Inc. (NASDAQ: CTY) on October 19, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the purchase was executed at a price of $18.00 per share, bringing the total transaction value to $3.06 million.
CTY
City Therapeutics, Inc.
Robert Nelsen vs. the S&P 500
Hypothetical returns from Robert Nelsen's disclosed trades, not real profit or advice. How we model this.
Inside Robert Nelsen's City Therapeutics Trade
The insider purchase grew Nelsen's direct holdings by about 1.26%, pushing his total share count to 13,692,507 shares following the transaction. The buy order was completed entirely in the open market and was not part of a pre-arranged Rule 10b5-1 trading plan.
City Therapeutics, Inc. Stock Down 4.2%
Shares of the biotechnology company recently traded around $21.46. The stock sits roughly 4.2% below both its 50-day and 200-day moving averages, which hover around $22.40. The current price is about 10.1% below its 52-week high of $23.88 and roughly 4.7% above its 52-week low of $20.50.
Recent Earnings
For its trailing twelve months, City Therapeutics reported total revenue of $14.34 million alongside a year-over-year revenue growth rate of 14.0%. The Cambridge-based firm carries a net margin of 0.0% as it continues to invest in its clinical pipeline.
About City Therapeutics, Inc.
City Therapeutics, Inc. is a biopharmaceutical company located in Cambridge, Massachusetts, with a team of 75 employees. The firm centers its research on developing RNA interference medicines by engineering small interfering RNAs. Its pipeline targets multiple therapeutic areas, with a specific focus on ophthalmologic conditions such as retinal diseases and geographic atrophy.
Bottom Line
Director trades of this size draw attention to how insiders manage their personal exposure to the business. Investors tracking City Therapeutics will likely watch upcoming financial reports and operational updates for further signals on the firm's pipeline progress.
Related Filing Alerts
Source: Robert Nelsen's Form 4 filing on $CTY (Oct 19, 2026). Written by software, not financial advice. How we make alerts